Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
Roivant (ROIV) reported financial results for Q3 2024 with consolidated cash, equivalents, restricted cash, and marketable securities of $5.2 billion. The company announced expansion of brepocitinib development into cutaneous sarcoidosis, with Phase 2 study initiation expected in Q2 2025.
Key financial metrics include R&D expenses increasing to $141.6 million from $108.1 million year-over-year, and G&A expenses rising to $141.5 million from $128.2 million. The company reported a loss from continuing operations of $208.9 million, compared to income of $5.1 billion in the same period last year.
Notable developments include Immunovant's $450 million private placement, bringing Roivant's ownership to 57%, and the initiation of pivotal trials for IMVT-1402 in Graves' disease and rheumatoid arthritis. Multiple clinical milestones are expected in 2025, including batoclimab results in myasthenia gravis and CIDP by March 31, 2025.
Roivant (ROIV) ha riportato i risultati finanziari per il Q3 2024 con un totale di cassa consolidata, equivalenti, cassa vincolata e titoli negoziabili di 5,2 miliardi di dollari. L'azienda ha annunciato l'espansione dello sviluppo di brepocitinib nella sarcoidosi cutanea, con l'inizio dello studio di Fase 2 previsto per il secondo trimestre del 2025.
I principali indicatori finanziari includono un aumento delle spese per R&S a 141,6 milioni di dollari rispetto ai 108,1 milioni dello stesso periodo dell'anno scorso, e un aumento delle spese generali e amministrative a 141,5 milioni di dollari rispetto ai 128,2 milioni. L'azienda ha registrato una perdita dalle operazioni continuate di 208,9 milioni di dollari, rispetto a un reddito di 5,1 miliardi di dollari nello stesso periodo dell'anno scorso.
Sviluppi significativi includono il collocamento privato di Immunovant di 450 milioni di dollari, portando la proprietà di Roivant al 57%, e l'inizio dei trial decisivi per IMVT-1402 nella malattia di Graves e nell'artrite reumatoide. Sono attesi molteplici traguardi clinici nel 2025, inclusi i risultati di batoclimab nella miastenia grave e nella CIDP entro il 31 marzo 2025.
Roivant (ROIV) informó sobre los resultados financieros del tercer trimestre de 2024, con efectivo consolidado, equivalentes, efectivo restringido y valores negociables de 5.2 mil millones de dólares. La compañía anunció la expansión del desarrollo de brepocitinib en sarcoidosis cutánea, con el inicio del estudio de Fase 2 previsto para el segundo trimestre de 2025.
Los principales indicadores financieros incluyen un aumento en los gastos de I+D a 141.6 millones de dólares desde los 108.1 millones del año anterior, y un aumento en los gastos generales y de administración a 141.5 millones de dólares desde los 128.2 millones. La compañía reportó una pérdida de operaciones continuas de 208.9 millones de dólares, en comparación con un ingreso de 5.1 mil millones de dólares en el mismo período del año pasado.
Desarrollos notables incluyen una colocación privada de Immunovant de 450 millones de dólares, elevando la propiedad de Roivant al 57%, y el inicio de ensayos clave para IMVT-1402 en la enfermedad de Graves y artritis reumatoide. Se esperan múltiples hitos clínicos en 2025, incluidos los resultados de batoclimab en miastenia gravis y CIDP para el 31 de marzo de 2025.
Roivant (ROIV)는 2024년 3분기 재무 결과를 보고했으며, 총 52억 달러의 현금, 현금성 자산, 제한된 현금 및 시장성 증권을 기록했습니다. 이 회사는 피부 사르코이드증에 대한 brepocitinib 개발을 확장한다고 발표했으며, 2025년 2분기에는 2상 연구가 시작될 것으로 예상됩니다.
주요 재무 지표로는 R&D 비용이 지난해 1억 8,100만 달러에서 1억 4,160만 달러로 증가하였고, 일반 관리 비용은 1억 2,820만 달러에서 1억 4,150만 달러로 상승했습니다. 이 회사는 지속 운영에서 2억 8,890만 달러의 손실을 기록했으며, 이는 작년 같은 기간에 51억 달러의 수익과 비교됩니다.
주목할 만한 발전으로는 Immunovant의 4억 5천만 달러 사모 배치가 있으며, 이는 Roivant의 지분을 57%로 높입니다. 또한 Graves 병과 류마티스 관절염에 대한 IMVT-1402의 중요한 시험이 시작됩니다. 2025년에는 중증 근무력증과 CIDP에 대한 batoclimab 결과가 2025년 3월 31일까지 예정되어 있습니다.
Roivant (ROIV) a annoncé ses résultats financiers pour le T3 2024, avec des liquidités consolidées, des équivalents de liquidités, des liquidités restreintes et des titres négociables totalisant 5,2 milliards de dollars. L'entreprise a annoncé l'expansion du développement de brepocitinib dans la sarcoïdose cutanée, avec le début de l'étude de phase 2 prévu pour le T2 2025.
Les principaux indicateurs financiers incluent des dépenses en R&D augmentant à 141,6 millions de dollars contre 108,1 millions de dollars d'une année sur l'autre, et des dépenses générales et administratives passant à 141,5 millions de dollars contre 128,2 millions de dollars. L'entreprise a enregistré une perte des opérations continues de 208,9 millions de dollars, comparativement à un revenu de 5,1 milliards de dollars au cours de la même période l'année dernière.
Les développements notables incluent un placement privé de Immunovant de 450 millions de dollars, portant la propriété de Roivant à 57%, et le lancement d'essais décisifs pour IMVT-1402 dans la maladie de Graves et l'arthrite rhumatoïde. De multiples jalons cliniques sont attendus en 2025, y compris les résultats de batoclimab pour la myasthénie et la CIDP d'ici le 31 mars 2025.
Roivant (ROIV) berichtete über die finanziellen Ergebnisse für das 3. Quartal 2024 mit konsolidierten liquiden Mitteln, Zahlungsmitteläquivalenten, eingeschränkten Zahlungsmitteln und handelbaren Sicherheiten in Höhe von 5,2 Milliarden US-Dollar. Das Unternehmen gab die Erweiterung der Entwicklung von brepocitinib auf kutane Sarkoidose bekannt, wobei der Beginn der Phase-2-Studie für das 2. Quartal 2025 erwartet wird.
Wichtige Finanzkennzahlen sind unter anderem die Forschung- und Entwicklungsausgaben, die auf 141,6 Millionen US-Dollar von 108,1 Millionen US-Dollar im Jahresvergleich gestiegen sind, sowie die allgemeinen und Verwaltungskosten, die auf 141,5 Millionen US-Dollar von 128,2 Millionen US-Dollar gestiegen sind. Das Unternehmen berichtete von einem Verlust aus fortgeführten Tätigkeiten in Höhe von 208,9 Millionen US-Dollar, verglichen mit einem Einkommen von 5,1 Milliarden US-Dollar im gleichen Zeitraum des Vorjahres.
Bemerkenswerte Entwicklungen umfassen Immunovants Privatplatzierung in Höhe von 450 Millionen US-Dollar, die Roivants Eigentum auf 57% erhöht, sowie den Beginn richtungsweisender Studien für IMVT-1402 bei der Morbus Basedow und rheumatoide Arthritis. Im Jahr 2025 werden mehrere klinische Meilensteine erwartet, darunter die Ergebnisse von batoclimab bei Myasthenia gravis und CIDP bis zum 31. März 2025.
- Strong cash position of $5.2 billion as of December 31, 2024
- Received $75 million regulatory milestone payment for VTAMA approval
- Raised $450 million through Immunovant private placement
- Expanded clinical pipeline with new brepocitinib indication
- Loss from continuing operations of $208.9 million in Q3
- R&D expenses increased by $33.4 million to $141.6 million
- G&A expenses increased by $13.4 million to $141.5 million
- Phase 2 study of namilumab failed to show treatment benefit
Insights
Roivant's Q3 FY2025 results demonstrate a robust financial foundation and strategic execution across multiple fronts. The $5.2 billion cash position, supplemented by
The expansion into cutaneous sarcoidosis with brepocitinib represents a calculated move into an orphan indication affecting 30,000-50,000 US patients with no approved therapies. This strategy of targeting high-unmet-need markets with potential first-in-class treatments could drive significant value creation.
The increased R&D investment, particularly the
The financial performance shows disciplined capital allocation despite increased expenses. The $327 million gain from the Dermavant sale demonstrates successful value realization from portfolio management. The ongoing Moderna litigation regarding LNP technology, progressing toward a September 2025 trial, represents a potential significant value driver.
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update.
- Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026
- IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves’ disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated
- Batoclimab topline results from pivotal trial in myasthenia gravis (MG) and initial results from period 1 of trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025
- Progress in ongoing LNP litigation, with the summary judgment phase in the Moderna case taking place across the second and third quarters of calendar year 2025 and a jury trial scheduled for September 2025
- Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately
$5.2 billion at December 31, 2024, not including a one-time regulatory milestone of$75 million received in January for the approval of VTAMA in atopic dermatitis and$113 million of external capital raised in Immunovant’s January private placement
“Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in cutaneous sarcoidosis. As with dermatomyositis and non-infectious uveitis, brepocitinib has the potential to be a first-in-class agent for CS and expands the treatment options for patients suffering from an indication with high unmet need,” said Matt Gline, CEO of Roivant. “We also look forward to announcing multiple significant study outcomes this year including for batoclimab in MG, CIDP and TED, and for brepocitinib in dermatomyositis. 2025 is a year of harvest for Roivant.”
Recent Developments
- Immunovant:
In January 2025, Immunovant announced a$450 million private placement with participation from a U.S.-based healthcare focused investor, a large mutual fund complex, and Roivant, bringing Roivant’s basic ownership up to approximately57% .
Endocrinology Program
Immunovant recently initiated the first potentially registrational trial of IMVT-1402 in adult participants with GD who are hyperthyroid despite antithyroid drug (ATD) treatment. This study builds on the batoclimab proof-of-concept data presented in 2024, which suggest the potential for deep IgG reduction in the treatment of GD for patients who are not well controlled on ATDs.
Rheumatology Program
Immunovant recently initiated a potentially registrational trial of IMVT-1402 in adult participants with active, anti-citrullinated protein autoantibody (ACPA) positive difficult-to-treat rheumatoid arthritis. The trial includes IMVT-1402’s higher dose (600 mg) as recent in-class data suggest that deeper ACPA reduction correlated with better clinical improvement in ACPA+ RA patients treated with an FcRn inhibitor.
- Priovant: In February 2025, Priovant announced a Phase 2 study of the safety and efficacy of brepocitinib in adults with cutaneous sarcoidosis. Cutaneous sarcoidosis marks the third indication for brepocitinib and continues the strategy to develop the drug in orphan indications with high unmet need. There are 30,000 to 50,000 patients in the US affected by cutaneous sarcoidosis with no approved therapies. The trial is expected to begin in the second quarter of calendar year 2025; topline results are expected in the second half of calendar year 2026.
- Genevant: The Pfizer / BioNTech Markman hearing was held in December 2024.
- Roivant: Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately
$5.2 billion at December 31, 2024, not including a one-time regulatory milestone of$75 million received in January for the approval of VTAMA in atopic dermatitis and$113 million of external capital raised in Immunovant’s January private placement.
In December 2024, Roivant announced Kinevant’s Phase 2 study of namilumab failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. Kinevant is discontinuing further development of namilumab for the treatment of sarcoidosis.
Major Upcoming Milestones
- Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026.
Neurology Program
Immunovant intends to report topline results from the pivotal trial of batoclimab in MG by March 31, 2025. Results from this trial are expected to inform a decision regarding next steps for batoclimab in MG and inform the design of a potentially registrational program for IMVT-1402 in MG, which Immunovant expects to initiate following the disclosure of the batoclimab data in MG.
Results from period one of the trial evaluating batoclimab in CIDP continue to be expected by March 31, 2025. Those results, as well as observations drawn from public disclosures of other studies in CIDP, are expected to inform a potentially registrational program for IMVT-1402 in CIDP, which Immunovant expects to initiate following the disclosure of the batoclimab CIDP data.
Endocrinology Program
Immunovant plans to announce additional data from the batoclimab proof-of-concept study in GD including 6-month, treatment-free remission data designed to further articulate potential for IMVT-1402 in GD. These data are expected in the summer of 2025.
Topline results from the pivotal program of batoclimab for the treatment of thyroid eye disease (TED), also known as Graves' ophthalmopathy, continue to be expected in the second half of calendar year 2025, along with a decision whether to pursue marketing authorization for batoclimab in TED. Data from this trial may also inform the IMVT-1402 program in GD.
- Priovant plans to report topline data from the ongoing Phase 3 trial of brepocitinib in DM in the second half of calendar year 2025 and topline data from the ongoing Phase 3 trial of brepocitinib in NIU in the first half of calendar year 2027.
Priovant’s Phase 2 trial of brepocitinib in cutaneous sarcoidosis is expected to begin in the second quarter of calendar year 2025; topline results are expected in the second half of calendar year 2026.
- Pulmovant plans to report topline data from the ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease in the second half of calendar year 2026.
- Genevant litigation against Moderna continues to progress with summary judgment phase scheduled for second and third quarter of calendar year 2025; Moderna jury trial scheduled for September 2025.
Third Quarter Ended December 31, 2024 Financial Summary
Cash Position and Marketable Securities
As of December 31, 2024, the Company had consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately
Research and Development Expenses
Research and development (R&D) expenses increased by
Within program-specific costs, the increase of
Non-GAAP R&D expenses were
General and Administrative Expenses
General and administrative (G&A) expenses increased by
Non-GAAP G&A expenses were
Income (loss) from discontinued operations, net of tax
Income from discontinued operations, net of tax was
(Loss) income from continuing operations, net of tax
Loss from continuing operations, net of tax was
| ROIVANT SCIENCES LTD. | |||||
| Selected Balance Sheet Data | |||||
| (unaudited, in thousands) | |||||
| December 31, 2024 | March 31, 2024 | ||||
| Cash, cash equivalents and restricted cash | $ | 2,001,674 | $ | 6,506,189 | |
| Marketable securities | 3,155,825 | — | |||
| Total assets | 5,792,345 | 7,222,482 | |||
| Total liabilities | 256,375 | 773,953 | |||
| Total shareholders’ equity | 5,535,970 | 6,448,529 | |||
| Total liabilities and shareholders’ equity | 5,792,345 | 7,222,482 | |||
| ROIVANT SCIENCES LTD. | |||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||
| (unaudited, in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Nine Months Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue, net | $ | 9,018 | $ | 15,562 | $ | 21,483 | $ | 23,693 | |||||||
| Operating expenses: | |||||||||||||||
| Cost of revenues | 259 | 197 | 706 | 1,403 | |||||||||||
| Research and development (includes | 141,595 | 108,148 | 405,175 | 332,354 | |||||||||||
| Acquired in-process research and development | — | — | — | 26,450 | |||||||||||
| General and administrative (includes | 141,545 | 128,172 | 444,318 | 308,030 | |||||||||||
| Total operating expenses | 283,399 | 236,517 | 850,199 | 668,237 | |||||||||||
| Gain on sale of Telavant net assets | — | 5,348,410 | 110,387 | 5,348,410 | |||||||||||
| (Loss) income from operations | (274,381 | ) | 5,127,455 | (718,329 | ) | 4,703,866 | |||||||||
| Change in fair value of investments | 21,314 | 10,467 | (42,287 | ) | 63,880 | ||||||||||
| Change in fair value of liability instruments | (2,147 | ) | (2,492 | ) | (1,632 | ) | 49,475 | ||||||||
| Gain on deconsolidation of subsidiaries | — | — | — | (17,354 | ) | ||||||||||
| Interest income | (61,851 | ) | (31,953 | ) | (203,751 | ) | (62,967 | ) | |||||||
| Other expense (income), net | 2,816 | (2,112 | ) | 7,877 | 2,245 | ||||||||||
| (Loss) income from continuing operations before income taxes | (234,513 | ) | 5,153,545 | (478,536 | ) | 4,668,587 | |||||||||
| Income tax (benefit) expense | (25,568 | ) | 22,365 | (1,147 | ) | 27,276 | |||||||||
| (Loss) income from continuing operations, net of tax | (208,945 | ) | 5,131,180 | (477,389 | ) | 4,641,311 | |||||||||
| Income (loss) from discontinued operations, net of tax | 327,020 | (58,515 | ) | 373,030 | (227,609 | ) | |||||||||
| Net income (loss) | 118,075 | 5,072,665 | (104,359 | ) | 4,413,702 | ||||||||||
| Net loss attributable to noncontrolling interests | (51,306 | ) | (23,519 | ) | (138,853 | ) | (86,339 | ) | |||||||
| Net income attributable to Roivant Sciences Ltd. | $ | 169,381 | $ | 5,096,184 | $ | 34,494 | $ | 4,500,041 | |||||||
| Amounts attributable to Roivant Sciences Ltd.: | |||||||||||||||
| (Loss) income from continuing operations, net of tax | $ | (157,639 | ) | $ | 5,154,466 | $ | (338,691 | ) | $ | 4,726,682 | |||||
| Income (loss) from discontinued operations, net of tax | 327,020 | (58,282 | ) | 373,185 | (226,641 | ) | |||||||||
| Net income attributable to Roivant Sciences Ltd. | $ | 169,381 | $ | 5,096,184 | $ | 34,494 | $ | 4,500,041 | |||||||
| Net income per common share, basic: | |||||||||||||||
| (Loss) income from continuing operations, net of tax | $ | (0.22 | ) | $ | 6.44 | $ | (0.46 | ) | $ | 6.09 | |||||
| Income (loss) from discontinued operations, net of tax | $ | 0.45 | $ | (0.07 | ) | $ | 0.51 | $ | (0.29 | ) | |||||
| Net income per common share | $ | 0.23 | $ | 6.37 | $ | 0.05 | $ | 5.79 | |||||||
| Net income per common share, diluted: | |||||||||||||||
| (Loss) income from continuing operations, net of tax | $ | (0.22 | ) | $ | 6.10 | $ | (0.46 | ) | $ | 5.73 | |||||
| Income (loss) from discontinued operations, net of tax | $ | 0.45 | $ | (0.07 | ) | $ | 0.51 | $ | (0.27 | ) | |||||
| Net income per common share | $ | 0.23 | $ | 6.03 | $ | 0.05 | $ | 5.46 | |||||||
| Weighted average shares outstanding: | |||||||||||||||
| Basic | 722,716,168 | 800,587,716 | 731,318,202 | 776,759,728 | |||||||||||
| Diluted | 722,716,168 | 844,461,685 | 731,318,202 | 824,310,013 | |||||||||||
| ROIVANT SCIENCES LTD. | ||||||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||||||||||||
| (unaudited, in thousands) | ||||||||||||||||||
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||||||||
| Note | 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| (Loss) income from continuing operations, net of tax | $ | (208,945 | ) | $ | 5,131,180 | $ | (477,389 | ) | $ | 4,641,311 | ||||||||
| Adjustments: | ||||||||||||||||||
| Research and development: | ||||||||||||||||||
| Share-based compensation | (1 | ) | 9,685 | 6,913 | 30,128 | 22,639 | ||||||||||||
| Depreciation and amortization | (2 | ) | 728 | 1,023 | 2,147 | 3,717 | ||||||||||||
| General and administrative: | ||||||||||||||||||
| Share-based compensation | (1 | ) | 69,386 | 44,419 | 165,670 | 120,891 | ||||||||||||
| Depreciation and amortization | (2 | ) | 1,083 | 1,199 | 3,267 | 3,684 | ||||||||||||
| Gain on sale of Telavant net assets | (3 | ) | — | (5,348,410 | ) | (110,387 | ) | (5,348,410 | ) | |||||||||
| Other: | ||||||||||||||||||
| Change in fair value of investments | (4 | ) | 21,314 | 10,467 | (42,287 | ) | 63,880 | |||||||||||
| Change in fair value of liability instruments | (5 | ) | (2,147 | ) | (2,492 | ) | (1,632 | ) | 49,475 | |||||||||
| Gain on deconsolidation of subsidiaries | (6 | ) | — | — | — | (17,354 | ) | |||||||||||
| Estimated income tax impact from adjustments | (7 | ) | (34,786 | ) | 17,666 | (38,976 | ) | 18,035 | ||||||||||
| Adjusted loss from continuing operations, net of tax (Non-GAAP) | $ | (143,682 | ) | $ | (138,035 | ) | $ | (469,459 | ) | $ | (442,132 | ) | ||||||
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||||
| Note | 2024 | 2023 | 2024 | 2023 | ||||||||||
| Research and development expenses | $ | 141,595 | $ | 108,148 | $ | 405,175 | $ | 332,354 | ||||||
| Adjustments: | ||||||||||||||
| Share-based compensation | (1 | ) | 9,685 | 6,913 | 30,128 | 22,639 | ||||||||
| Depreciation and amortization | (2 | ) | 728 | 1,023 | 2,147 | 3,717 | ||||||||
| Adjusted research and development expenses (Non-GAAP) | $ | 131,182 | $ | 100,212 | $ | 372,900 | $ | 305,998 | ||||||
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||||
| Note | 2024 | 2023 | 2024 | 2023 | ||||||||||
| General and administrative expenses | $ | 141,545 | $ | 128,172 | $ | 444,318 | $ | 308,030 | ||||||
| Adjustments: | ||||||||||||||
| Share-based compensation | (1 | ) | 69,386 | 44,419 | 165,670 | 120,891 | ||||||||
| Depreciation and amortization | (2 | ) | 1,083 | 1,199 | 3,267 | 3,684 | ||||||||
| Adjusted general and administrative expenses (Non-GAAP) | $ | 71,076 | $ | 82,554 | $ | 275,381 | $ | 183,455 | ||||||
Notes to non-GAAP financial measures:
(1) Represents non-cash share-based compensation expense.
(2) Represents non-cash depreciation and amortization expense.
(3) Represents a one-time gain on the sale of Telavant net assets to Roche in December 2023 and a gain on the achievement of a one-time milestone in June 2024.
(4) Represents the unrealized loss (gain) on equity investments in unconsolidated entities that are accounted for at fair value with changes in value reported in earnings.
(5) Represents the change in fair value of liability instruments, which is non-cash and primarily includes the unrealized (gain) loss relating to the measurement and recognition of fair value on a recurring basis of certain liabilities.
(6) Represents the one-time gain on deconsolidation of subsidiaries.
(7) Represents the estimated tax effect of the adjustments.
Investor Conference Call Information
Roivant will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a corporate update.
To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
What was Roivant's (ROIV) cash position at the end of Q3 2024?
How much did Roivant's (ROIV) R&D expenses increase in Q3 2024?
What was the size of Immunovant's private placement in January 2025 for ROIV?
When will Roivant (ROIV) report batoclimab trial results for myasthenia gravis?
What was Roivant's (ROIV) net loss from continuing operations in Q3 2024?
